San Francisco-based Bunkerhill Health has received clearance from the U.S. Food and Drug Administration (FDA) for its AI algorithm for detecting and quantifying mitral annular calcification (MAC).
Called Bunkerhill MAC, the algorithm was designed to detect mitral annular calcification -- a chronic condition in which calcium deposits build up in the mitral valve ring -- on nongated chest CT scans performed for noncardiac indications. Often discovered incidentally, studies have linked MAC to increased cardiovascular risk, including higher rates of mortality and complications in structural heart procedures, Bunkerhill said.
The algorithm was developed and tested on data from a multi-institutional research consortium of more than 25 academic medical centers, the company added.














![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&h=112&q=70&w=112)




